value crypto coins Top stories

Hisense Jia Shaoqian: Brand building is very hard work, which requires long-term persistence and a lot of money. The annual meeting of Caijing 2025: Forecast and Strategy and 2024 Global Wealth Management Forum was held in Beijing from December 13th to December 15th. Jia Shaoqian, Chairman of Hisense Group, delivered a speech. Jia Shaoqian pointed out that whether it is globalization or transformation, the key to the success of strategy lies in persistence and implementation to the end. He bluntly said that branding is a very hard job, which requires long-term persistence and a lot of money. Hisense firmly believes in the power of brands, that brands are the future of enterprises, and that there is no internationalization of Hisense without the internationalization of brands. "Especially when most China enterprises take advantage of the dividends from entering the market and borrow ships to go out to sea through OEM to make quick money, Hisense voluntarily gave up OEM and chose the most difficult shipbuilding to go out to sea, that is, resolutely went to the high end and invested a lot of money, people and resources in brand building, especially in corporate marketing." He said. (Rui Jian)Bank of China Securities Guan Tao: As long as the economy is stable and risks are prevented, the spring of China's capital market can be expected. The Central Economic Work Conference will be held in Beijing from December 11th to 12th. Guan Tao, global chief economist of Bank of China Securities, said that the meeting continued the policy thinking since the end of September and emphasized the need to implement more active and promising macro policies. Among them, implementing a more active fiscal policy is an important point to strengthen unconventional countercyclical adjustment. I believe that as long as the economy is stable and risks are prevented, the spring of China's capital market can be expected.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Zhouming Technology: cooperated with Byte Volcano and Bean Bag to access TTS and big model question-and-answer ability. Zhouming Technology said on the interactive platform that Zhouming Technology cooperated with Microsoft, Tencent, Baidu, Iflytek, Byte Volcano and Bean Bag on the self-developed UniAvatar digital human system. Among them, in May 2024, Zhouming Digital Man was able to access Volcano Engine's TTS capability and bean bag's big model question-and-answer capability, which was suitable for digital man dialogue system and other application scenarios.Ali launched the e-commerce app "Tao" in Japan: in the future, it will expand its staff to explore the local market. On December 12, Alibaba Group held a briefing on the e-commerce app "Tao" launched for the Japanese market. The company said that it will expand its staff in the future and fully explore the Japanese market. According to reports, the APP was launched in October, selling more than 3 million kinds of goods such as clothing, groceries and digital related products. It also has the function of recommending goods by artificial intelligence (AI) according to consumers' preferences. The goods are mainly delivered from China after the consumer places an order, and arrive in Japan a few days later. (Interface News)On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)

Kunlun Unicom and Anheng Information signed a cooperation agreement. On December 11th, Beijing Kunlun Unicom Technology Development Co., Ltd. and Anheng Information signed a cooperation agreement for Beijing regional general generation in Beijing. In this cooperation, Kunlun Unicom will rely on Anheng Information's professional technology and products in the field of digital security to further enrich its solution system and provide customers with more comprehensive information technology services. At the same time, Anheng Information will also rely on Kunlun Unicom's extensive customer resources and market channels to expand its market business in Beijing.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Shengyi Technology: The total sales volume of the company's rigid copper clad laminate ranks second in the world. Shengyi Technology said at the collective exchange meeting of investors that according to the statistics and ranking of the global rigid copper clad laminate in 2023 by Prismark of the United States, the total sales volume of the company's rigid copper clad laminate ranks second in the world, with a global market share of 14%. Regarding the growth trend of AI server, the company said that the upgrade iteration of hardware equipment related to AI server is fast, and the product form is quite different from that of previous wired products. The company can quickly respond to customer requirements and provide solutions. It is expected that AI applications will gradually develop from large model training to application in the future, and it is expected to achieve good growth.